Compare Amgen, Inc. (AMGN) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Jones Lang LaSalle Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Jones Lang LaSalle Inc trades at $324.44 (market cap $15.05B). The key difference: Amgen, Inc. is far larger — about 13× Jones Lang LaSalle Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| AMGN | JLL | |
|---|---|---|
Market Cap | $196.12B | $15.05B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $358.66 |
52-Week Low | $271.18 | $248.95 |
Enterprise Value | $241.41B | $18.59B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JLL trades at $324.44, showing modest daily gains with strong technical momentum and bullish moving averages. The company demonstrates solid fundamental improvement with revenue growth to $26.12B in 2025 and consistent earnings beats. Recent news highlights significant financing deals and Fortune 500 ranking improvement, reflecting strong business execution in commercial real estate services.
JLL presents a compelling investment case with 25% upside to consensus price target of $405.50, supported by improving profitability and positive analyst sentiment. Key risks include commercial real estate market cyclicality and competitive pressures. The stock's current valuation metrics (P/E 17.45, P/S 0.58) appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
